Thirty Years of the Drug Candidate NAMI‐A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

As anticipated in the title, this contribution is basically divided into two, strictly connected, parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 years after its synthesis and the discovery of its unprecedented antimetastatic properties in animal models at n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of inorganic chemistry Jg. 2017; H. 12; S. 1549 - 1560
1. Verfasser: Alessio, Enzo
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Weinheim Wiley Subscription Services, Inc 27.03.2017
Schlagworte:
Animals
Antitumor agents
Biological activity
Cancer
Dosage
Drug discovery
Drugs
Hypotheses
Inorganic chemistry
Medicinal chemistry
Pharmaceutical industry
Ruthenium
Sheets
Synthesis
ISSN:1434-1948, 1099-0682
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As anticipated in the title, this contribution is basically divided into two, strictly connected, parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 years after its synthesis and the discovery of its unprecedented antimetastatic properties in animal models at nontoxic dosages. The sections relating to the chemical and biological behavior of the complex, and the hypotheses on its mechanism(s) of action, are kept to a minimum, whereas more space is devoted to discussion of the results of the clinical investigations. The second part deals in detail with a number of undemonstrated misconceptions (or myths) that, over the years, have thrived around NAMI‐A and other ruthenium drug candidates, thus negatively affecting the whole field of Ru anticancer drugs. Almost 30 years after the discovery of NAMI‐A, and after two clinical phase studies have been accomplished, the time seems to be appropriate for drawing up a balance sheet. The undemonstrated misconceptions (or myths) that, over the years, have thrived around NAMI‐A and other ruthenium drug candidates are also critically addressed in detail.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1434-1948
1099-0682
DOI:10.1002/ejic.201600986